Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Genprex ( (GNPX) ) is now available.
On May 7, 2025, Genprex announced a new Sponsored Research Agreement with the University of Pittsburgh to conduct preclinical studies on GPX-002, a gene therapy for Type 1 and Type 2 diabetes. The preclinical data showed promising results, with significant decreases in insulin requirements and improvements in glucose tolerance in animal models, suggesting GPX-002 could be a groundbreaking treatment for diabetes.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for diabetes and cancer. The company is known for its innovative approaches to treating Type 1 and Type 2 diabetes, utilizing gene therapy constructs to potentially transform treatment paradigms.
Average Trading Volume: 4,746,807
Technical Sentiment Signal: Sell
Current Market Cap: $7.06M
For an in-depth examination of GNPX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money